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Haematological and non-haematological malignancies are able to escape the host immune by the 
capacity to hijack the immune check-points. Several immune check-point molecules are known, such 
as T cell immunoglobulin mucin-3 (TIM-3), cytotoxic T-cell antigen-4 (CTLA-4), programmed 
death-1 (PD-1) with its ligand PD-L1 and others.1 The function of these immune check-points is to 
prevent the damage resulting from an excessive activation of the immune response in the setting of 
chronic antigenic stimulation, thus leading to autoimmune phenomena, as proved in knock-out mice 
models. PD-1 is normally present on activated T lymphocytes membrane, acting as a negative 
costimulatory receptor. 
PD-L1 is constitutively expressed at low levels by resting lymphocytes, antigen presenting cells and 
certain immunologically privileged tissues like placenta and testis. 
PD-L1 expression can be induced as well. In an inflammatory/infective context when T cells 
recognize antigens expressed by MHC-complex they start to produce inflammatory cytokines. The 
resulting inflammation leads to the expression of PD-L1 by hematopoietic, epithelial and endothelial 
cells, activating PD-1 on the surface of T-cells and therefore blocking the immune response. 
Previous studies have found out that PD-1 is highly expressed on T-reg cells and their binding with 
PD-L1 enhances suppressor T-reg functions2,3; the activation of PD-1/PD-L1 pathway reduces the 
lytic capacity of NK cells and B cell antibody production.  
In solid neoplasms PD-L1 expression by cancer cells and persistent up-regulation of PD-1 by tumour-
infiltrating lymphocytes is common45. All these findings brought to the development of check-point 
inhibitors in the contest of solid tumors and lymphoproliferative neoplasms such as lymphoma and 
myeloma where the immune checkpoint blockade treatment have shown efficacy in 
refractory/relapsed neoplasms6. Few investigations only have been conducted on the role of PD-
1/PD-L1 in myeloid neoplasms, such as acute myeloid leukemia, a haematological cancer 
characterised by high-risk of relapse and poor prognosis.  
In leukemia, the bone marrow serves as a sanctuary for neoplastic cells, these cells interact with the 
tumour microenvironment (TME), constituted by stromal cells, endothelial cells and immune cells. 
The marked activation of the PD-1/PD-L1 pathway contributes to the maintenance of an 
immunosuppressive microenvironment. In fact, blasts are able, through the production of 
immunoinhibitory factors, to suppress the function of immunosurveillance and immuno-elimination 
of the tumor by the effector T cells. The effector T cells are "exhausted" in their capacity to secrete 
granzyme B, perforine and interferon gamma, and there is an upregulation of the T-reg functions, in 
addition to the presence of myeloid-derived suppressor cells7. 
PD-L1 expression and his link with PD-1 on activated lymphocytes results in an impaired antitumoral 
activity in murine models8. Zhang et al. investigated the role of PD-1/PD-L1 engagement in murine 
AML showing that PD-1 -/- mice generated augmented antitumoral response in comparison with wild 
type mice. Similar results were obtained using anti-PD-L1 antibodies.9  
A study from Zhou et al. reported how the function of adoptively transferred AML-reactive CTLs 
was reduced by AML-associated Tregs and how Treg depletion followed by PD-1/PD-L1 blockade 
showed efficacy for AML eradication in murine models.10 
 
Objective of the study.   
To assess the presence of PD-1 and PD-L1 positive cells, by immunohistochemistry, in bone marrow 
biopsies of patients with AML. 
 
Material and methods.  
Four micron thickness sections were obtained from the formalin-fixed paraffin-embedded specimens. 
Haematoxylin-eosin staining was performed to assess the morphologic features of bone marrow. 
Immunohistochemical stainings were performed using a Ventana Benchmark Ultra automated 









NAT105, Ventana) and anti-PD-L1 (clone 22C3, Dako) antibodies.  
 
Results.  
We obtained 34 bone marrow trephine biopsies from newly diagnosed AML patients, 17 males and 
17 females with a 67.3 mean age. We used 10 healthy bone marrow specimens as normal controls. 
None out of 10 control bone marrows resulted positive for either PD-1 or PD-L1 expressing cells as 
expected. Eleven out of 34 AML bone marrows (32,4%) showed at least 1% of PD-L1 positive cells 
(fig.2 b,d,f), while 6 AML bone marrow samples (17,6%) were positive for at least 1% of PD-1+ cells 
(fig. 1 b).  
 
Discussion.  
Despite the presence of relevant preclinical data regarding the role of immune check-points, few 
studies to evaluate the PD1/PDL1 axis have been conducted in myeloid neoplasm. Jia et al. performed 
flow cytometry analysis on PBMCs and BMMCs of 22 newly diagnosed AML patients and observed 
a significantly increased frequency of PD-1 expressing CD8 T cells in bone marrow compared to 
peripheral blood, suggesting a more exhausted status of these cells in relation to the suppressive 
environment11. Dail et al. measured PD-L1 expression in 7 AML patients using 
immunohistochemistry and flow cytometry and found that PD-L1 was detectable (>2% cells) in all 
patients.12 Yang et al. assessed 45 bone marrow biopsies of MDS, CMML and AML patients and 
found that leukemic blasts of 9 patients (20%) were PD-L1+, while 3 (7%) were positive for PD-1. 
All 4 controls tested were negative for both PD-1 and PD-L1.13 Daver et al. measured PD-1 
expression on bone marrow aspirates of 74 AML patients using flow cytometry. The results showed 
higher PD-1 expression compared to healthy controls (n=8).14  
To our this is the largest study evaluating by immunohistochemistry the expression of PD-1 and PD-
L1 in AML bone marrows and shows a significative positivity of the activation of the PD-1/PD-L1 
pathway which gives a rationale to further studies regarding the charateristics of the cells involved in 
the PD-1/PD-L1 pathway and the immunosuppressive microenvironment. 
An implementation of the PD-1/PD-L1 pathway evaluation in clinical setting could have prognostic 
significance since the expression of PD-L1 by AML blasts has been associated with poor-risk and 
intermediate-risk AML15, furthermore immune checkpoint inhibitors have shown promising results 
in maintenance treatment of high-risk AML16, underlining not only a prognostic but also therapeutic 











Figure 1 – PD-1 expression 
Acute myeloid leukemia evolved from chronic myeloid leukemia (a); presence of approximately 20% 
of CD34 + myeloid blasts (b); PD-1 expression in about 4% of myeloid blasts (c). 
a: hematoxylin-eosin staining, 200x;  
b: CD34 immunohistochemical staining, 200x;  













Figure 2 – PD-L1 expression  
(a-b) Acute myeloid leukemia with myelodysplastic changes, with marrow infiltration by a blast 
population CD34 / MPO; Focal expression of PD-L1 in a myeloid blast  (b). 
(c-d) Acute myeloblastic leukemia with submassive medullary infiltration (blasts MPO+/CD34+ = 
85%); PD-L1 + expression in 6% of myeloid blasts (d). 
(e-f) Acute myeloid leukemia (blasts MPO+/CD34+ = 30%); PD-L1 expression in 2% of myeloid 
blasts (f). 
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